TIF is a renowned brand that focuses on improving the lives of patients with various blood disorders, specifically thalassaemia and haemoglobinopathies. Through their extensive work and collaborations, TIF strives to provide education, support, and effective care to patients worldwide. One of their notable achievements is the Global Thalassaemia Review 2022 (GTR), a comprehensive publication highlighting the challenges faced by thalassaemia patients and their families.

With nearly 500 pages, it sheds light on the disease burden and emphasizes the need for accessible and quality healthcare services. Furthermore, TIF offers the THALIA App, a self-management tool that empowers patients with thalassaemia to take control of their condition. This user-friendly app provides valuable resources and information at their fingertips.

TIF also conducts clinical trials and keeps healthcare professionals and associations updated on the latest developments through their Clinical Trial Updates. They actively engage with patients and emphasize the importance of patient perspectives in research. Overall, TIF is dedicated to enhancing the quality of life for individuals with blood disorders by advocating for better care, conducting research, and providing valuable resources to patients and healthcare professionals